Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
ConclusionsThe combination of TMZ-treatment leading to up-regulation and/or cytoplasmic accumulation of CAPs, with FC-immunotherapy as a means of producing specific immunity against CAPs, may safely induce anti-tumor effects in patients with GBM.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Brain Tumor | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Chemotherapy | Glioma | Immunotherapy | Polyethylene Glycol | Temodar | Toxicology | Vaccines